Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond
- PMID: 25790161
- PMCID: PMC4993715
- DOI: 10.1038/gim.2015.23
Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond
Erratum in
-
CORRIGENDUM: Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond.Genet Med. 2015 Jun;17(6):515. doi: 10.1038/gim.2015.64. Genet Med. 2015. PMID: 26035804 No abstract available.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Karow J. NIPS continues to take off in 2013 as indications, insurance coverage grow. GenomeWeb. 2014 Jan 2;
-
- United Healthcare. Noninvasive prenatal diagnosis of fetal aneuploidy using cell-free fetal nucleic acids in maternal blood - policy no 2014T0560E. 2014 Apr 1; Https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/A....
-
- Flessel M, Goldman S. California prenatal screening program to include noninvasive testing. Acog.org2013;http://www.acog.org/About_ACOG/ACOG_Departments/District_Ne....
-
- Driscoll DA. Prenatal diagnosis of the 22q11. 2 deletion syndrome. Genetics in Medicine. 2001;3(1):14–8. - PubMed
-
- Vora NL, O’Brien BM. Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies. Obstetrics & Gynecology. 2014 May;123(5):1097–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
